论文部分内容阅读
目的评价羧甲司坦口服液治疗年龄>65岁肺炎患者咳嗽、咳痰的临床疗效。方法将52例年龄>65岁肺炎患者分为必漱平组(对照组)和羧甲司坦口服液组(观察组)各26例。结果羧甲司坦口服液治疗>65岁肺炎的临床症状、体征的总有效率为76.9%。总祛痰率80.8%。患者在临床疗效、祛痰作用临床评价等方面其治疗后评分均较治疗前有显著改善(P<0.05).特别是祛痰疗效,有更显著改善。结论羧甲司坦口服液用于>65岁肺炎咳嗽、咳痰的临床疗效显著,特别是痰液黏稠、排痰困难患者,使用安全,疗效肯定。
Objective To evaluate the clinical efficacy of carbocisteine oral liquid in the treatment of cough and sputum in patients with pneumonia aged> 65 years. Methods A total of 52 patients with pneumonia aged> 65 years were divided into two groups: beijing tablet (control group) and carbocisteine oral solution group (observation group). Results Carbetolitan oral solution of> 65-year-old pneumonia clinical symptoms, signs of the total effective rate was 76.9%. The total expectorant rate of 80.8%. Patients in the clinical efficacy, the clinical evaluation of expectorant effect after treatment scores were significantly improved compared with before treatment (P <0.05), especially the expectorant effect, there is more significant improvement. Conclusion Carboxystain oral solution for> 65 years of pneumonia, cough, sputum clinical significant effect, especially sputum viscosity, expectoration difficulties in patients with safe use, efficacy is positive.